212 related articles for article (PubMed ID: 31783084)
1. Nanoparticle-enabled blood tests for early detection of pancreatic ductal adenocarcinoma.
Caputo D; Caracciolo G
Cancer Lett; 2020 Feb; 470():191-196. PubMed ID: 31783084
[TBL] [Abstract][Full Text] [Related]
2. Nanotechnology Meets Oncology: A Perspective on the Role of the Personalized Nanoparticle-Protein Corona in the Development of Technologies for Pancreatic Cancer Detection.
Caputo D; Quagliarini E; Pozzi D; Caracciolo G
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142503
[TBL] [Abstract][Full Text] [Related]
3. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
[TBL] [Abstract][Full Text] [Related]
4. Improving the accuracy of pancreatic cancer clinical staging by exploitation of nanoparticle-blood interactions: A pilot study.
Caputo D; Cartillone M; Cascone C; Pozzi D; Digiacomo L; Palchetti S; Caracciolo G; Coppola R
Pancreatology; 2018 Sep; 18(6):661-665. PubMed ID: 29914752
[TBL] [Abstract][Full Text] [Related]
5. Protein-metabolite panel for early-stage pancreatic cancer.
Burki TK
Lancet Oncol; 2018 Oct; 19(10):e512. PubMed ID: 30146244
[No Abstract] [Full Text] [Related]
6. Advances in pancreatic cancer research: moving towards early detection.
He XY; Yuan YZ
World J Gastroenterol; 2014 Aug; 20(32):11241-8. PubMed ID: 25170208
[TBL] [Abstract][Full Text] [Related]
7. A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma.
Pang Y; Holmes MV; Chen Z; Kartsonaki C
J Gastroenterol Hepatol; 2019 Feb; 34(2):330-345. PubMed ID: 30550622
[TBL] [Abstract][Full Text] [Related]
8. The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer.
Kunovsky L; Tesarikova P; Kala Z; Kroupa R; Kysela P; Dolina J; Trna J
Can J Gastroenterol Hepatol; 2018; 2018():5389820. PubMed ID: 30186820
[TBL] [Abstract][Full Text] [Related]
9. Development of serum parameters panels for the early detection of pancreatic cancer.
Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
[TBL] [Abstract][Full Text] [Related]
10. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
[TBL] [Abstract][Full Text] [Related]
11. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.
Hanna-Sawires RG; Schiphuis JH; Wuhrer M; Vasen HFA; van Leerdam ME; Bonsing BA; Mesker WE; van der Burgt YEM; Tollenaar RAEM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800786
[TBL] [Abstract][Full Text] [Related]
12. Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review.
Yako YY; Kruger D; Smith M; Brand M
PLoS One; 2016; 11(5):e0154016. PubMed ID: 27170998
[TBL] [Abstract][Full Text] [Related]
13. Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma.
Llop E; E Guerrero P; Duran A; Barrabés S; Massaguer A; José Ferri M; Albiol-Quer M; de Llorens R; Peracaula R
World J Gastroenterol; 2018 Jun; 24(24):2537-2554. PubMed ID: 29962812
[TBL] [Abstract][Full Text] [Related]
14. Converting the personalized biomolecular corona of graphene oxide nanoflakes into a high-throughput diagnostic test for early cancer detection.
Papi M; Palmieri V; Digiacomo L; Giulimondi F; Palchetti S; Ciasca G; Perini G; Caputo D; Cartillone MC; Cascone C; Coppola R; Capriotti AL; Laganà A; Pozzi D; Caracciolo G
Nanoscale; 2019 Aug; 11(32):15339-15346. PubMed ID: 31386742
[TBL] [Abstract][Full Text] [Related]
15. Efficient pancreatic cancer detection through personalized protein corona of gold nanoparticles.
Digiacomo L; Caputo D; Coppola R; Cascone C; Giulimondi F; Palchetti S; Pozzi D; Caracciolo G
Biointerphases; 2021 Feb; 16(1):011010. PubMed ID: 33706529
[TBL] [Abstract][Full Text] [Related]
16. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
17. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.
Udgata S; Takenaka N; Bamlet WR; Oberg AL; Yee SS; Carpenter EL; Herman D; Kim J; Petersen GM; Zaret KS
Cancer Prev Res (Phila); 2021 Feb; 14(2):223-232. PubMed ID: 33067248
[TBL] [Abstract][Full Text] [Related]
18. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
[TBL] [Abstract][Full Text] [Related]
19. Potential biomarkers for early detection of pancreatic ductal adenocarcinoma.
Kriz D; Ansari D; Andersson R
Clin Transl Oncol; 2020 Dec; 22(12):2170-2174. PubMed ID: 32447642
[TBL] [Abstract][Full Text] [Related]
20. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma.
Gold DV; Gaedcke J; Ghadimi BM; Goggins M; Hruban RH; Liu M; Newsome G; Goldenberg DM
Cancer; 2013 Feb; 119(3):522-8. PubMed ID: 22898932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]